Affimed N V's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Affimed N V (AFMD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Affimed N V vs Its Competitors
- TTM: Trailing 12-month revenue of 9M vs 672,961M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months), vs accelerating (+48.6%) for its tracked peer group.
- Growth: Affimed N V generated -80.0% revenue growth year over year in Q4 2023, vs -0.3% for its tracked competitors combined.
- Profitability: Its -1,280.2% net margin compares with 14.7% for the peer group.
- Peer revenue share: Affimed N V accounted for 0.0% of combined revenue among its tracked peer group, down from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.09M compares with $1.00M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AFMD Sales vs. its Competitors, Q4 2023
Affimed N V reported revenue contraction of 79.99 % year on year in Q4 2023, below its competitors' combined revenue change of -0.34 %.
With a net margin of -1,280.22 %, Affimed N V reported lower profitability than its competitors (14.69 %).
Affimed N V generated 0.00 % of the combined sales of its peer group, down from 0.02 % a year earlier.
Affimed N V vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Affimed N V and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Affimed N v | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Affimed N V's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs -80.0% for Affimed N V. Affimed N V's share of combined industry revenue moved from 0.01% to 0.00%, a loss of 0.01 percentage points.
Affimed N V's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Affimed N v | - | - | - | - |
| Competitors combined (205) | ||||
| High-Confidence Competitors (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AFMD Stock Performance relative to its Competitors
AFMD Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Gt Biopharma Inc | 282.9% | Outperformed |
| 4 | Erasca Inc | 282.9% | Outperformed |
| 5 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Affimed N V's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Affimed N V's Comment on Competition and Industry Peers
Publicly Traded Peers of Affimed N v
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Affimed N v | 2.76 | 8.95 |
| Eli Lilly And Company | 1,034,082.40 | 79,665.80 |
| Johnson and Johnson | 645,992.07 | 97,929.00 |
| Abbvie Inc | 463,275.89 | 64,386.00 |
| Merck and Co Inc | 359,088.60 | 66,569.00 |
| Novartis Ag | 278,724.35 | 56,674.00 |
| SUBTOTAL | 4,279,381.52 | 705,978.66 |
Sign in to see all competitors of Affimed N v .
Sources: Affimed N v's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Affimed N v versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Affimed N V's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Nkgen Biotech Inc | Named by the company | 85% |
| Aptevo Therapeutics Inc | Named by the company | 85% |
| Macrogenics Inc | Named by the company | 85% |
| ADAPTIN BIO, INC. | Named by the company | 85% |
| Xencor Inc | Named by the company | 85% |
| Eli Lilly And Company | Named by the company | 85% |
| Immunogen inc | Named by the company | 85% |
| Merck and Co Inc | Named by the company | 85% |
| Zymeworks Inc | Named by the company | 85% |
| Adicet Bio Inc | Named by the company | 85% |
| Takeda Pharmaceutical Company Limited | Named by the company | 85% |
| Johnson and Johnson | Named by the company | 85% |
| Bristol myers Squibb Company | Named by the company | 85% |
| Adc Therapeutics Sa | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Affimed N V's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Affimed N V's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Affimed N V's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Affimed N v | 3 | 87,752 | -1,123,422 |
| Eli Lilly And Company | 1,034,082 | 1,593,316 | 534,224 |
| Johnson and Johnson | 645,992 | 695,518 | 149,411 |
| Abbvie Inc | 463,276 | 1,129,579 | 110,807 |
| Merck and Co Inc | 359,089 | 887,587 | 42,267 |
| Novartis Ag | 278,724 | 752,973 | 185,566 |
| PEERS TOTAL | 4,279,379 | 998,690 | 150,819 |
Affimed N V's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Affimed N V's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Affimed N V's industry classification, broader than the peer set above. Market cap in millions of $.Affimed N V ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,060,478 | 19.39 % |
| 2 | Johnson and Johnson | 652,141 | 11.92 % |
| 3 | Beone Medicines Ltd | 560,341 | 10.24 % |
| 4 | Abbvie Inc | 468,722 | 8.57 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Affimed N v | - | 0.00 % |
Market cap and industry share for the rest of Affimed N V's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-15.
Affimed N V's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Affimed N V's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Affimed N V's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Affimed N V's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+314.2% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of tracked competitors (49.50 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Affimed N V's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Affimed N v | 1.49 | 3.25 | 0.11 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Affimed N V's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Affimed N v | Q4 2023 | -79.5 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| PEERS TOTAL | +10.4 % | -5.0 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Affimed N V's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Affimed N v | Q4 2023 | - | +481.0 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
Affimed N V's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Affimed N v | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Affimed N V's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Affimed N v | - | 0.31 |
| Eli Lilly And Company | 38.84 | 12.98 |
| Johnson and Johnson | 30.64 | 6.60 |
| Abbvie Inc | 73.90 | 7.20 |
| Merck and Co Inc | 117.24 | 5.39 |
| Novartis Ag | 19.93 | 4.92 |
| PEERS AVERAGE | 40.18 | 6.06 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.